tbuckley/cabot-search huggingface dataset:
Revascularization of ischemic limbs after transplantation of human bone marrow cells with high aldehyde dehydrogenase activity
Authors: Benjamin J. Capoccia, Debra L. Robson, Krysta D. Levac, Dustin J. Maxwell, Sarah A. Hohm, Marian J. Neelamkavil, Gillian I. Bell, Anargyros Xenocostas, Daniel C. Link, David Piwnica-Worms, Jan A. Nolta, David A. Hess
Journal: Blood (2009)
Pyoderma gangrenosum and myelofibrosis
Authors: None Cox
Journal: British Journal of Dermatology (1999)

Journal Article Pyoderma gangrenosum and myelofibrosis Get access Cox Cox Department of Dermatology, Cumberland Infirmary, Carlisle CA2 7HY, U.K. Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 140, Issue 2, 1 February 1999, Page 360, https://doi.org/10.1046/j.1365-2133.1999.02678.x Published: 01 February 1999
Trisomy 11 in myelodysplastic syndromes defines a unique group of disease with aggressive clinicopathologic features
Authors: S A Wang, K Jabbar, G Lu, S S Chen, N Galili, F Vega, D Jones, A Raza, H Kantarjian, G Garcia-Manero, T J McDonnell, L J Medeiros
Journal: Leukemia (2010)
Analysis of CD25hiCD4+ “regulatory” T-cell subtypes in atopic dermatitis reveals a novel TH2-like population
Authors: Amanda J. Reefer, Shama M. Satinover, Michael D. Solga, Joanne A. Lannigan, Jennifer T. Nguyen, Barbara B. Wilson, Judith A. Woodfolk
Journal: Journal of Allergy and Clinical Immunology (2008)
Lactitol in the treatment of chronic hepatic encephalopathy: an open comparison with lactulose.
Authors: P L Lanthier, M Y Morgan
Journal: Gut (1985)

Lactulose is currently the drug of choice for the treatment of hepatic encephalopathy. It is, however, only available as a syrup which is contaminated with other sugars. Consequently patients may express aversion to its excessively sweet taste and many experience nausea because of its hyperosmolarity. Lactitol is a disaccharide analogue of lactulose which can be produced as a pure crystalline powder with a low relative sweetness. Theoretically it should have the same therapeutic effects as lactulose but fewer side effects. Five patients with chronic hepatic encephalopathy on maintenance lactulose were monitored clinically, psychometrically, and by measurement of venous blood ammonia, electroencephalogram mean cycle frequency, and cerebral blood flow during three months treatment with lactulose and a similar period on lactitol. Lactitol was at least as efficacious as lactulose but was more acceptable because its cathartic effect was more predictable, its formulation was more convenient and its less sweet taste preferred. Lactitol is the ideal successor to lactulose for treatment of this condition.
Designer aminoglycosides prevent cochlear hair cell loss and hearing loss
Authors: Markus E. Huth, Kyu-Hee Han, Kayvon Sotoudeh, Yi-Ju Hsieh, Thomas Effertz, Andrew A. Vu, Sarah Verhoeven, Michael H. Hsieh, Robert Greenhouse, Alan G. Cheng, Anthony J. Ricci
Journal: Journal of Clinical Investigation (2015)

Bacterial infections represent a rapidly growing challenge to human health. Aminoglycosides are widely used broad-spectrum antibiotics, but they inflict permanent hearing loss in up to ~50% of patients by causing selective sensory hair cell loss. Here, we hypothesized that reducing aminoglycoside entry into hair cells via mechanotransducer channels would reduce ototoxicity, and therefore we synthesized 9 aminoglycosides with modifications based on biophysical properties of the hair cell mechanotransducer channel and interactions between aminoglycosides and the bacterial ribosome. Compared with the parent aminoglycoside sisomicin, all 9 derivatives displayed no or reduced ototoxicity, with the lead compound N1MS 17 times less ototoxic and with reduced penetration of hair cell mechanotransducer channels in rat cochlear cultures. Both N1MS and sisomicin suppressed growth of E. coli and K. pneumoniae, with N1MS exhibiting superior activity against extended spectrum β lactamase producers, despite diminished activity against P. aeruginosa and S. aureus. Moreover, systemic sisomicin treatment of mice resulted in 75% to 85% hair cell loss and profound hearing loss, whereas N1MS treatment preserved both hair cells and hearing. Finally, in mice with E. coli–infected bladders, systemic N1MS treatment eliminated bacteria from urinary tract tissues and serially collected urine samples, without compromising auditory and kidney functions. Together, our findings establish N1MS as a nonototoxic aminoglycoside and support targeted modification as a promising approach to generating nonototoxic antibiotics.
Altered expression of the mRNA stability factor HuR promotes cyclooxygenase-2 expression in colon cancer cells
Authors: Dan A. Dixon, Neal D. Tolley, Peter H. King, L. Burt Nabors, Thomas M. McIntyre, Guy A. Zimmerman, Stephen M. Prescott
Journal: Journal of Clinical Investigation (2001)

Cyclooxygenase-2 (COX-2) expression is normally tightly regulated. However, constitutive overexpression plays a key role in colon carcinogenesis. To understand the molecular nature of enhanced COX-2 expression detected in colon cancer, we examined the ability of the AU-rich element-containing (ARE-containing) 3' untranslated region (3'UTR) of COX-2 mRNA to regulate rapid mRNA decay in human colon cancer cells. In tumor cells displaying enhanced growth and tumorigenicity that is correlated with elevated COX-2, vascular endothelial growth factor (VEGF), and IL-8 protein levels, the corresponding mRNAs were transcribed constitutively and turned over slowly. The observed mRNA stabilization is owing to defective recognition of class II-type AREs present within the COX-2, VEGF, and IL-8 3'UTRs; c-myc mRNA, containing a class I ARE decayed rapidly in the same cells. Correlating with cellular defects in mRNA stability, the RNA-binding of trans-acting cellular factors was altered. In particular, we found that the RNA-stability factor HuR binds to the COX-2 ARE, and overexpression of HuR, as detected in tumors, results in elevated expression of COX-2, VEGF, and IL-8. These findings demonstrate the functional significance rapid mRNA decay plays in controlling gene expression and show that dysregulation of these trans-acting factors can lead to overexpression of COX-2 and other angiogenic proteins, as detected in neoplasia.
Abstract 3797: Hyperphosphorylation and desumoylation of RanGAP1·SUMO1
Authors: Irina Oussenko, James F. Holland, E. Premkumar Reddy, Takao Ohnuma
Journal: Cancer Research (2012)

Abstract Previous work from our laboratory showed that tumor cells exposed to an anticancer mitotic inhibitor, regosertib (ON 01910.Na), resulted in G2/M arrest and hyperphosphorylation of RanGAP1·SUMO1 (HRGS). These findings suggest that regosertib may act either as an inhibitor of a RanGAP1·SUMO1 phosphatase or stimulant of a new kinase (Cancer Res 2011; 71; 4968-76). We further studied the relationship between dephosphorylation and deSUMOylation of HRGS. In the present study we used DU145 prostate cancer cell line. After exposure to one microM regosertib for 24 h, cells were collected and subjected, in equal portions, to lysis in different lysis buffers composed of basic lysis buffer and varied in supplemented inhibitors. Basic lysis buffer contained 10 mM Tris-HCl, pH 8.0; 150 mM NaCl; 1% Triton; 0.5% NP-40; 1 mM EGTA and 1 mM EDTA. Thus, prepared cell lysates were analyzed by Western blot for expression of phosphorylated and non-phosphorylated forms of RanGAP1, RanGAP1·SUMO1, PP1 and Cdc25C. Results: Roche protease inhibitor cocktail, PMSF (0.5 mM), NaF (1 mM) and Na3VO4 (1mM) as inhibitors added to the basic lysis buffer were unable to protect against loss of SUMO-group from RanGAP1·SUMO1 and, concomitantly, against de-phosphorylation of PP1 phosphatase at T-320. However, addition of N-ethylmaleimide (NEM, an inhibitor of deSUMOylation) as a single inhibitor supplement in the basic lysis buffer resulted in concentration-dependent (2.5 ∼ 40mM) inhibition of deSUMOylation of HRGS. Yet, even at lower NEM concentration RanGAP1, devoid of the SUMO-group, was still phosphorylated. This might be in correlation with our finding that even low concentration of NEM in the lysis buffer kept PP1 in phosphorylated state at T320 (which is inhibitory to PP1), preventing it from auto-dephosphorylation and re-activation. Also, neither regosertib (up to 100 microM) nor okadaic acid (OA, up to 1 microM), added to the basic lysis buffer as putative inhibitors, could prevent loss of SUMO group from HRGS and dephosphorylation of PP1 at T320. Regosertib in the lysis buffer did not prevent dephosphorylation of hyperphosphorylated Cdc25C (aka mitotic Cdc25C), while NEM and OA did (the latter implies that dephosphorylation was carried out by PP1 in the lysate). Conclusion: These data show that hyperphosphorylated RanGAP1·SUMO1 can be deSUMOylated, but remains phosphorylated. DeSUMOylation may be a prerequisite for RanGAP dephosphosphorylation. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 3797. doi:1538-7445.AM2012-3797
Does Integrin-Mediated Cell Death Confer Tissue Tropism in Metastasis?
Authors: Jill M. Lahti, Tal Teitz, Dwayne G. Stupack
Journal: Cancer Research (2006)

Abstract To develop metastatic capability, tumor cells must evolve the capacity to survive in novel microenvironments. Recently, we showed that metastasis of neuroblastoma cells is enhanced by loss of caspase-8, an event that occurs frequently in this malignancy. In poorly metastatic cells, unligated integrins were found to trigger activation of caspase-8, providing a selective pressure to promote its attenuation and thereby increased survival in foreign adhesive environments. Our findings suggest one mechanism by which the organotropism of metastastic cancer cells can arise. (Cancer Res 2006; 66(12): 5981-4)
Oral Corticosteroid Therapy for Patients with Stable Chronic Obstructive Pulmonary Disease
Authors: Christopher M. Callahan, Robert S. Dittus, Barry P. Katz
Journal: Annals of Internal Medicine (1991)

Purpose: To evaluate the effectiveness of oral corticosteroid therapy in patients with stable chronic obstructive pulmonary disease. Data Identification: An English-language literature search using MEDLINE (1966 to 1989) and a bibliographic review of all retrieved articles identified 33 original studies of oral corticosteroid use in chronic obstructive pulmonary disease published since 1951. Study Selection: We submitted a photocopy of each study's "methods" section to three nonstudy physician-investigators who used nine explicit criteria to independently assess study quality. Ten studies met all criteria and five studies met some of the criteria. Data Extraction: To compare outcomes across all qualifying studies, we defined response to therapy as a 20% or greater increase in the baseline forced expiratory volume in 1 second (FEV1); we defined the treatment effect size for each study as the proportion of patients who responded to corticosteroid therapy minus the proportion of patients who responded to placebo. Potential confounding variables as related to eligibility criteria and treatment protocols were also assessed for each study. Results of Data Synthesis: Among ten studies that met all nine criteria, we found no significant differences in eligibility criteria, treatment protocol, or study design. No association was found between treatment effect size and publication date, study size, mean patient age, or FEV1. These studies had reported effect sizes ranging from 0% to 56%; we calculated a weighted mean effect size of 10% (95% CI, 2% to 18%). When studies meeting only some of the criteria were included in the calculation, the weighted mean effect size was 11% (95% CI, 4% to 18%). Conclusions: Patients with stable chronic obstructive pulmonary disease receiving oral corticosteroid therapy have a 20% or greater improvement in baseline FEV1 approximately 10% more often than similar patients receiving placebo.
Deletion of serine/arginine‐rich splicing factor 3 in hepatocytes predisposes to hepatocellular carcinoma in mice
Authors: Supriya Sen, Magda Langiewicz, Hassan Jumaa, Nicholas J.G. Webster
Journal: Hepatology (2014)

Alterations in RNA splicing are associated with cancer, but it is not clear whether they result from malignant transformation or have a causative role. We show here that hepatocyte-specific deletion of serine/arginine-rich splicing factor 3 (SRSF3) impairs hepatocyte maturation and metabolism in early adult life, and mice develop spontaneous hepatocellular carcinoma (HCC) with aging. Tumor development is preceded by chronic liver disease with progressive steatosis and fibrosis. SRSF3 protects mice against CCl4 -induced fibrosis and carcinogenesis and suppresses inclusion of the profibrogenic EDA exon in fibronectin 1. Loss of SRSF3 increases expression of insulin-like growth factor 2 and the A-isoform of the insulin receptor, allowing aberrant activation of mitogenic signaling, promotes aberrant splicing and expression of epithelial to mesenchymal transition (EMT) genes, and activates Wnt/β-catenin signaling leading to c-Myc induction. Finally, SRSF3 expression is either decreased or the protein mislocalized in human HCC.Our data suggest a potential role for SRSF3 in preventing hepatic carcinogenesis by regulating splicing to suppress fibrosis, mitogenic splicing, and EMT. Thus, these mice may provide an attractive model to discover the pathogenic mechanisms linking aberrant pre-messenger RNA splicing with liver damage, fibrosis, and HCC.
ESTROGEN TREATMENT OF PATIENTS WITH CHRONIC BRAIN SYNDROME ASSOCIATED WITH CEREBRAL ATHEROSCLEROSIS
Authors: KENNETH LIFSHITZ, NATHAN S. KLINE
Journal: American Journal of Psychiatry (1965)

For this severely impaired population of 37 patients suffering from chronic brain syndrome associated with cerebral atherosclerosis, treatment with 1.25 mg./day of conjugated equine estrogens over a period of about one year resulted in no measurable effect on psychological functioning or on mortality as compared to placebo treatment.
Computer prediction of the need for dialysis and transplantation using calculated creatinine clearance.
Authors: F W Ballardie, S Gartside, N P Mallick
Journal: BMJ (1983)

A computerised system capable of prospective assessment of the course of chronic renal failure has been devised. Rapid analysis is possible of the progress of a large cohort of patients and therefore of the prospective load on renal unit facilities. Calculated creatinine clearance values provide a more accurate and earlier prediction of end stage failure than the reciprocals of serum creatinine values.
PTU-247 ERCP—can a small volume unit provide a satisfactory service?
Authors: M Yiasemidou, S Stock
Journal: Gut (2012)

<h3>Introduction</h3> In recent years, systems grading ERCP technical difficulty have been introduced in UK clinical practice. According to these, small volume units are advised to refer complex cases to specialised centres. Conversely, in the US the American Society for Gastrointestinal Endoscopy (ASGE) has announced favourable results of community based hospitals ERCP success rates compared to university hospitals. Recommended competence rates are: 90% successful bile duct cannulation, 85% for bile duct stone removal and 90% for bile duct drainage of a blocked duct.<sup>1</sup> In the UK, the J.R.B. Green and the UK ERCP stakeholders working party and Joint Advisory Group (JAG) suggest an overall 80% success rate.<sup>2</sup> This study compares ERCP success rates in Nobles Hospital, a geographically isolated District General Hospital, to the competence rates of ASGE and JAG in order to assess whether ERCP can be performed successfully in district general hospitals in the UK. <h3>Methods</h3> Between December 2010 and January 2012, 42 ERCPs were performed on 36 patients (F:M 24:12, Mean age: 69.8). All procedures were done for therapeutic purposes. Indications were divided to two categories: jaundice-stones identified in biliary ducts on pre procedural imaging (n=21) and jaundice-causes besides stones were identified in pre procedural imaging (n=21). χ<sup>2</sup> Test was used to compare success ratios between Nobles Hospital and ASGE and JAG recommended levels. <h3>Results</h3> Desired duct cannulation success rate was 88.1% (n=37). Success rate for stone removal was 80.95% (n=17). For bile duct drainage of a blocked duct was 85.7% (n=18). Had ASGE recommended rates been applied to our hospital9s cases, the results would be: 38 out of 42, 18 out of 21 and 19 out of 21 respectively. No statistically significant difference was found between Nobles Hospital and ASGE figures (Successful cannulation p value=0.72, successful stone removal p value=0.68, successful blocked duct drainage=0.63). Overall success rate for Nobles was 83.3% (n=35). <h3>Conclusion</h3> ERCP success rates in Nobles Hospital are equivalent to the ASGE/ACG Task Force recommended competency levels and exceed JAG recommended success rates. This study provides evidence that ERCP can be successfully performed in a non-specialised environment within the British National Health System. <h3>Competing interests</h3> None declared. <h3>References</h3> 1. <b>ASGE publication</b>. “Quality Outcomes and Complication Rates for ERCP in a Community Hospital Setting Compare Favourably With Academic Centres”. http://www.asge.org 2. <b>Green JRB</b>, the UK ERCP Stakeholders Working Party. <i>The Future of Service and Training in ERCP in the UK—A Strategy</i>. http://www.bsg.org.uk
Fatal Flows — Doctors on the Move
Authors: Lincoln C. Chen, Jo Ivey Boufford
Journal: New England Journal of Medicine (2005)

The movement of physicians from poor to rich countries is a growing obstacle to global health. Ghana, with 0.09 physician per thousand population, sends doctors to the United Kingdom, which has 18 times as many physicians per capita. The United States, with 5 percent of the world's population, employs 11 percent of the globe's physicians, and its demand is growing.1 As underscored in the article by Mullan in this issue of the Journal, 2 today, 25 percent of U.S. physicians are international medical graduates, and the number is even higher in the United Kingdom, Canada, and Australia. Many of these graduates . . .
Thyroid abnormalities before and during treatment in patients with chronic hepatitis B or C
Authors: E. Rigopoulou, N. Pyrsopoulos, G. Bamias, E. Demertzi, A. Mitsopoulou, I. Valsami, M. Tsagaris, V. Papafragas, D. Tsantoulas
Journal: Journal of Hepatology (1998)
During EPO or anemia challenge, erythroid progenitor cells transit through a selectively expandable proerythroblast pool
Authors: Arvind Dev, Jing Fang, Pradeep Sathyanarayana, Anamika Pradeep, Christine Emerson, Don M. Wojchowski
Journal: Blood (2010)

Abstract Investigations of bone marrow (BM) erythroblast development are important for clinical concerns but are hindered by progenitor cell and tissue availability. We therefore sought to more specifically define dynamics, and key regulators, of the formation of developing BM erythroid cell cohorts. A unique Kit−CD71highTer119− “stage E2” proerythroblast pool first is described, which (unlike its Kit+ “stage E1” progenitors, or maturing Ter119+ “stage E3” progeny) proved to selectively expand ∼ 7-fold on erythropoietin challenge. During short-term BM transplantation, stage E2 proerythroblasts additionally proved to be a predominantly expanded progenitor pool within spleen. This E1→E2→E3 erythroid series reproducibly formed ex vivo, enabling further characterizations. Expansion, in part, involved E1 cell hyperproliferation together with rapid E2 conversion plus E2 stage restricted BCL2 expression. Possible erythropoietin/erythropoietin receptor proerythroblast stage specific events were further investigated in mice expressing minimal erythropoietin receptor alleles. For a hypomorphic erythropoietin receptor-HM allele, major defects in erythroblast development occurred selectively at stage E2. In addition, stage E2 cells proved to interact productively with primary BM stromal cells in ways that enhanced both survival and late-stage development. Overall, findings reveal a novel transitional proerythroblast compartment that deploys unique expansion devices.
The Vitamin Content of Certain Proprietary Preparations
Authors: K. H. Coward, A. J. Clark
Journal: BMJ (1923)

B , 3curve gradually falls until the copper value is reached.This suggests that besides a-f3 glucose, disaccharides or other substances with a polarimeter: copper reduction ratio greater than that of a-,8 glucose are present in the blood of diabetic persons.We suggest that a-, glucose cannot be directly stored or utilized, but that an enzyme is responsible for the conversion of a-,3 glucose into y glucose.We picture the
Video Recording of Medical Procedures—Reply
Authors: Martin Makary
Journal: JAMA (2013)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Too Much Borges
Authors: JOSEPH HERMAN
Journal: Annals of Internal Medicine (1985)

Ad Libitum1 August 1985Too Much BorgesJOSEPH HERMAN, M.D.JOSEPH HERMAN, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-103-2-301 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptMarch 14Dear Will,I'm sorry to be writing out of turn, but something incredible has transpired that I hasten to communicate. Volume 3 of the paperbackNew American Prose, which came into my hands a few days ago, contains a long chapter from a novel in progress by W.T. Suthers. The novel's protagonist is John Valgin, whose story is neither more nor less than a biography of the inner life you have, on occasion, confessed to me! On page 371, "Our Contributors," are a few un-illuminating details about the author, who lives in Maine with a wife, three children,... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Beth She'an Israel PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 August 1985Volume 103, Issue 2Page: 301-301KeywordsChildren Issue Published: 1 August 1985 PDF downloadLoading ...